Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis

Abstract Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) are the mainstay of treatment for hormone receptor positive, HER2 negative (HR + /HER2−) metastatic breast cancer (MBC). However, disease progression is inevitable and unveiling resistance mechanisms is crucial to...

Full description

Saved in:
Bibliographic Details
Main Authors: Letizia Pontolillo, Andrew A. Davis, Lorenzo Gerratana, Arielle J. Medford, Judy Wang, Eleonora Nicolo’, Katherine Clifton, Marko Velimirovic, Surbhi Warrior, Emily Podany, Eleni Andreopoulou, Mara Serena Serafini, Laura Munoz-Arcos, Elisabetta Molteni, Marla Lipsyc-Sharf, Caterina Gianni, Nadia Bayou, Charles S. Dai, Diana Giannarelli, Emilio Bria, Cynthia X. Ma, Aditya Bardia, Carolina Reduzzi, Massimo Cristofanilli
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-025-00802-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41523-025-00802-2

Similar Items